Global Liver Institute Welcomes Larry R. Holden as CEO
Global Liver Institute Welcomes Larry R. Holden as CEO
September 03, 2024 09:54 ET | Global Liver Institute
Washington, DC, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the...
SPRING Trial: Liver Stiffness Measurements Improved in CM-101-Treated Patients
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
July 25, 2024 07:00 ET | Chemomab Therapeutics
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
FDA’s Approval of Br
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
March 14, 2024 17:18 ET | Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
September 05, 2023 08:30 ET | Travere Therapeutics, Inc.
• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments• Mirum has acquired Travere’s rights and assets related to Cholbam® and...
Growth in Patient an
Growth in Patient and Medical Community Engagement in NASH Community Persists Despite Recent Regulatory Disappointment
June 08, 2023 07:19 ET | Global Liver Institute
Washington, D.C., June 08, 2023 (GLOBE NEWSWIRE) -- Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most...
ICER MIDWEST CEPAC W
ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES
May 01, 2023 17:36 ET | Global Liver Institute
Washington, DC, May 01, 2023 (GLOBE NEWSWIRE) -- On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic...
PATIENT GROUPS DECLA
PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES
April 28, 2023 12:22 ET | Global Liver Institute
Washington, DC, April 28, 2023 (GLOBE NEWSWIRE) -- Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid...
researchdrivelogo.jpg
Global Urinalysis Market Expected to Garner $4,776.9 Million in the 2021-2028 Timeframe, Growing at 6.3% CAGR [170-Pages] | Released by Research Dive
January 25, 2023 09:00 ET | Research Dive
New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global urinalysis market is predicted to rise at a tremendous CAGR of 6.3%, thereby...
VIR_logo_large.jpg
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
October 31, 2022 16:05 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program...
researchdrivelogo.jpg
Global Liver Disease Treatment Market Anticipated to Garner $32,028.5 Million, Growing with 11.7% CAGR in the 2021–2028 Timeframe [240-Pages] | Wrap up by Research Dive
October 12, 2022 08:59 ET | Research Dive
New York, USA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global liver disease treatment market. According to the report, the global market is projected to...